Tags

Type your tag names separated by a space and hit enter

Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris.
J Eur Acad Dermatol Venereol. 2009 Aug; 23(8):905-12.JE

Abstract

BACKGROUND AND OBJECTIVE

Treatment in psoriasis vulgaris continues to unmet needs in terms of efficacy, quality of life and costs. Patients with moderate forms of psoriasis are using topical corticosteroids as first-line therapy and patients with severe forms also use this therapy. Optimization of this treatment is made by the use of combination drugs or by the sequential or rotational therapies. A multicentric clinical study was performed to measure the efficiency of mometasone furoate 0.1% and salicylic acid 5% and mometasone furoate 0.1% as sequential local therapy in psoriasis.

METHODS

This was a randomized, multicentre trial with two patient groups receiving active treatment. The study group (N = 184) received mometasone furoate 0.1% and salicylic acid 5% for the first 7 days of treatment, and in the following 14 days, the patients used mometasone furoate 0.1%. The second group (N = 176) was treated with mometasone furoate 0.1% for 21 consecutive days. Psoriasis Area Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) were calculated.

RESULTS

After the first week of treatment in the study group, the reduction of PASI score was 44%, statistically significant greater than the reduction of PASI score in the second group (37%). Quality of life estimated by DLQI indicated significant lower values in the first (study) group.

CONCLUSION

The sequential treatment mometasone furoate 0.1% and salicylic acid 5% followed by mometasone furoate 0.1% proves to be efficient, safe and an excellent option for the following sequence: in-patient and out-patient.

Authors+Show Affiliations

Colentina Clinical Hospital, Bucharest, Romania. tiplica@b.astral.roNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19470062

Citation

Tiplica, G-S, and C M. Salavastru. "Mometasone Furoate 0.1% and Salicylic Acid 5% Vs. Mometasone Furoate 0.1% as Sequential Local Therapy in Psoriasis Vulgaris." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 23, no. 8, 2009, pp. 905-12.
Tiplica GS, Salavastru CM. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(8):905-12.
Tiplica, G. S., & Salavastru, C. M. (2009). Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology : JEADV, 23(8), 905-12. https://doi.org/10.1111/j.1468-3083.2009.03214.x
Tiplica GS, Salavastru CM. Mometasone Furoate 0.1% and Salicylic Acid 5% Vs. Mometasone Furoate 0.1% as Sequential Local Therapy in Psoriasis Vulgaris. J Eur Acad Dermatol Venereol. 2009;23(8):905-12. PubMed PMID: 19470062.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. AU - Tiplica,G-S, AU - Salavastru,C M, Y1 - 2009/03/11/ PY - 2009/5/28/entrez PY - 2009/5/28/pubmed PY - 2009/10/14/medline SP - 905 EP - 12 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 23 IS - 8 N2 - BACKGROUND AND OBJECTIVE: Treatment in psoriasis vulgaris continues to unmet needs in terms of efficacy, quality of life and costs. Patients with moderate forms of psoriasis are using topical corticosteroids as first-line therapy and patients with severe forms also use this therapy. Optimization of this treatment is made by the use of combination drugs or by the sequential or rotational therapies. A multicentric clinical study was performed to measure the efficiency of mometasone furoate 0.1% and salicylic acid 5% and mometasone furoate 0.1% as sequential local therapy in psoriasis. METHODS: This was a randomized, multicentre trial with two patient groups receiving active treatment. The study group (N = 184) received mometasone furoate 0.1% and salicylic acid 5% for the first 7 days of treatment, and in the following 14 days, the patients used mometasone furoate 0.1%. The second group (N = 176) was treated with mometasone furoate 0.1% for 21 consecutive days. Psoriasis Area Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) were calculated. RESULTS: After the first week of treatment in the study group, the reduction of PASI score was 44%, statistically significant greater than the reduction of PASI score in the second group (37%). Quality of life estimated by DLQI indicated significant lower values in the first (study) group. CONCLUSION: The sequential treatment mometasone furoate 0.1% and salicylic acid 5% followed by mometasone furoate 0.1% proves to be efficient, safe and an excellent option for the following sequence: in-patient and out-patient. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/19470062/Mometasone_furoate_0_1_and_salicylic_acid_5_vs__mometasone_furoate_0_1_as_sequential_local_therapy_in_psoriasis_vulgaris_ L2 - https://doi.org/10.1111/j.1468-3083.2009.03214.x DB - PRIME DP - Unbound Medicine ER -